Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 895929 | ISIN: CH0012142631 | Ticker-Symbol: CLRN
Lang & Schwarz
18.01.25
13:04 Uhr
10,705 Euro
0,000
0,00 %
1-Jahres-Chart
CLARIANT AG Chart 1 Jahr
5-Tage-Chart
CLARIANT AG 5-Tage-Chart
RealtimeGeldBriefZeit
10,65010,76018.01.
0,0000,00028.03.23
PR Newswire
355 Leser
Artikel bewerten:
(2)

LBB Specialties LLC: LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications

Finanznachrichten News

NORWALK, Conn., Dec. 4, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will distribute Clariant's pharmaceutical-grade high-functional excipients - including their polyethylene glycols (PEGs) and VitiPure® portfolio - for ophthalmic applications in the North American Life Sciences market.

LBB Specialties Logo

This partnership brings together LBB Specialties' established expertise in the ophthalmic market with Clariant's decades-long experience in producing and supplying high-quality PEGs, a critical component in many ophthalmic formulations.

Clariant's pharmaceutical-grade PEGs, now part of LBB Specialties' innovative Life Sciences portfolio, ensure customers have access to high-performance ingredients designed for various ophthalmic products. From eye drops to gels, the addition of these PEGs strengthens LBB Specialties' ability to meet the evolving demands of the pharmaceutical industry.

"At LBB Specialties, we're committed to providing our customers with the highest quality specialty pharmaceutical ingredients," said Seth Burns, Senior Vice President of Life Sciences at LBB Specialties. "Partnering with Clariant allows us to deliver industry-leading PEGs that offer consistency and performance for ophthalmic applications, providing our customers with the assurance they need throughout the pharmaceutical lifecycle-from R&D to commercialization."

"This partnership with LBB Specialties marks a significant step in our commitment to serving the pharmaceutical industry," said Vaios Barlas, Head of Health Care at Clariant. "Our focus on developing high-performance, pharmaceutical-grade excipients has consistently pushed the boundaries of what's possible in ophthalmic formulations. By leveraging LBB Specialties' strong distribution network in North America, we can ensure that more formulators and manufacturers can access our cutting-edge ingredients, ultimately driving innovation in ophthalmic applications."

To learn more about Clariant's PEGs and how they can benefit your products, contact LBB Specialties today.

About LBB Specialties
LBB Specialties is a leader in North American specialty chemicals and ingredients distribution. It is a diversified supplier serving end markets including care, food & nutrition, industrial specialties, and life sciences. www.LBBSpecialties.com.

About Clariant
Clariant is a focused specialty chemical company led by the overarching purpose of "Greater chemistry - between people and planet." By connecting customer focus, innovation, and people, the company creates solutions to foster sustainability in different industries. On December 31, 2023, Clariant totaled a staff number of 10,481 and recorded sales of CHF 4.377 billion in the fiscal year for its continuing businesses. Since January 2023, the Group conducts its business through the three Business Units: Care Chemicals, Catalysts, and Adsorbents & Additives. Clariant is based in Switzerland.

Clariant Health Care is a leading high-quality solution partner for the global pharmaceutical industry, with a strong portfolio of top-performing excipients and active pharmaceutical ingredients (APIs), backed by operational excellence and years of experience in regulatory affairs. https://www.clariant.com/HealthCare

Media Contact:
Ahmed Hanafy
media@lbbspecialties.com

Logo - https://mma.prnewswire.com/media/2537440/LBB_Specialties_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/lbb-specialties-and-clariant-partner-to-distribute-high-quality-pharmaceutical-grade-pegs-for-ophthalmic-applications-302322973.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.